medigraphic.com
ISSN 1817-5996 (Electronic)

2021, Number 2

<< Back Next >>

Rev Cub de Reu 2021; 23 (2)

Macrophage activation syndrome as a complication of systemic juvenile idiopathic arthritis

Gómez CSY, Carrión MR, del Toro RLM, Chia PD

Language: Spanish
References: 22
Page:
PDF size: 277.16 Kb.


ABSTRACT

Systemic Juvenile Idiopathic Arthritis, also known as Still's disease, is considered an autoinflammatory disorder and is often the most complex and severe of all clinical forms of the disease. It usually takes the form of repeated bouts of activity, interspersed with periods of remission. We present the case of a 4-year-old female patient, diagnosed with Still's disease at 2 years of age. Currently undergoing treatment with triple induction therapy: chloroquine, methotrexate and salazosulfapyridine with persistently high disease activity due to JADAS 27. He comes to the clinic due to fever, general condition, and respiratory manifestations of three days of evolution interpreted as an infectious respiratory process under. Antibiotic treatment is started without signs of improvement. At 7 days the clinical picture worsens, and the diagnosis of Macrophage Activation Syndrome is raised. A steroid treatment protocol is started in combination with other drugs of proven efficacy for this clinical situation (ethopside, cyclosporine, methotrexate). Antibiotic policy was reassessed without achieving a satisfactory response and it was decided to introduce rituximab, which provides excellent results. After three months of difficult management, the patient was released from the hospital recovered from this complication and with a low level of activity of the underlying disease.


REFERENCES

  1. Athreya BH. Is macrophage activation syndrome a new entity? Clin Exp Rheumatology. 2002 [Acceso 05/06/2020];20(2):121-3. PubMed PMID: 12051388. Disponible en: https://scholar.google.es/scholar?q=Is+macrophage+activation+syndrome+a+new+entity%3F+&hl=es&as_sdt=0,5

  2. Egües Dubuc C, Aldasoro Cáceres V, Uriarte Ecenarro M, Errazquin Aguirre N, Hernando Rubio I, Meneses Villalba CF, et al. Síndrome de activación macrofágica secundario a enfermedades autoinmunes, hematológicas, infecciosas y oncológicas. Serie de 13 casos clínicos y una revisión bibliográfica. Reumatología Clinica. 2015 [Acceso 05/06/2020];11(3):139-43 Disponible en: https://www.sciencedirect.com/science/article/pii/S1699258X1400134X

  3. García Consuegra Molina J, Merino Muñoz R, de Inocencio Arocena J. Síndrome de activación macrofágica y artritis idiopática juvenil. Resultados de un estudio multicéntrico. Anales de Pediatría. 2008 [Acceso 05/06/2020];68(2):110-116. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1695403308749002

  4. Usmani GN, Woda BA, Newburger PE. Advances in understanding the pathogenesis of HLH. Br J Haematol. 2013 [Acceso 05/06/2020];161(5):609-22. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.12293

  5. Schulert GS, Grom AA. Macrophage activation syndrome and cytokine directed therapies. Best Pract Res Clin Rheumatol. 2015 [Acceso 06/06/2020];28(2):277-92. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1521694214000199

  6. Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine directed therapies. Annu Rev Med. 2015 [Acceso 06/06/2020];66:145-59. Disponible en: https://www.annualreviews.org/doi/abs/10.1146/annurev-med-061813-012806

  7. Bracaglia C, Prencipe G, de Benedetti F. Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome. Pediatric Rheumatology. 2017 [Acceso 11/06/2020];15(1):5. Disponible en: https://ped-rheum.biomedcentral.com/articles/10.1186/s12969-016-0130-4

  8. Andrés M, López Gómez JM. Síndrome de activación macrofágica en paciente con enfermedad de Still. Rev Sociedad Val Reuma. 2008 [Acceso 05/06/2020];2(5):41-3. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=3122120

  9. Torres Jiménez A. Síndrome de activación de macrófago como manifestación inicial de lupus eritematoso sistémico severo de inicio juvenil. Respuesta favorable a ciclofosfamida. Reumatol Clin. 2014 [Acceso 05/06/2020];10(5):331-5.Disponible en: https://www.sciencedirect.com/science/article/pii/S1699258X13001836

  10. Stephan JL, Kone Paut I, Galambrun C, Mouy R, Bader Meunier B, Prieur AM. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford). 2001 [Acceso 07/06/2020];40(11):1285-92. Disponible en: https://academic.oup.com/rheumatology/article/40/11/1285/1784069?login=true

  11. Sterba G, Sterba Y, Iglesias AG. Síndrome de activación macrofágica en adultos. Rev Colombiana Reumatol. 2016 [Acceso 04/06/2020];23(2):137-43. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0121812315001243

  12. Martini AF, Cron RQ. Criterios de clasificación del SAM en la AIJs. Modificado de Ravelli A, Davi S, Minoia. Macrophage Activation Syndrome. Hematology/Oncology Clinics of North America. 2015 Oct;29(5):927-41. AÑO

  13. Henter JI. Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2017 [Acceso 10/06/2020];48:124-31. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/pbc.21039

  14. Kumakura S. Hemophagocytic syndrome. Intern Med Apr. 2005 [Acceso 09/06/2020];44(4):278-80. Disponible en: https://www.jstage.jst.go.jp/article/internalmedicine/44/4/44_4_278/_article/-char/ja/

  15. Ravelli A, Magni Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005 [Acceso 05/06/2020];146(1):598-604 Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0022347604011680

  16. Ruiz O, Gallón C, González T. Síndrome de activación macrofágica como complicación de una artritis idiopática juvenil de tipo sistémico: Reporte de un caso. Cienc Innov Salud. 2017 [Acceso 11/06/2020];4(2):1-5. Disponible en: https://revistas.unisimon.edu.co/index.php/innovacionsalud/article/download/2630/3310

  17. Wallace CA, Sherry DD. Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritis and Rheum. 2019 [Acceso 09/06/2020];40(10):1852-55. PubMed PMID: 9336421. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.1780401019

  18. Coca A, Bundy KW, Marston B, Huggins J, Looney RJ. Macrophage activation syndrome: serological markers and treatment with antithymocyte globulin. Clinical Immunology. 2009 [Acceso 07/06/2020];132(1):10-8. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1521661609000485

  19. Remesal Camba A, Merino Muñoz R. Síndrome de activación del macrófago. Protoc Diagn Ter Pediatr. 2014 [Acceso 03/06/2020];1:49-56. Disponible en: https://www.aeped.es/sites/default/files/documentos/06_sd_activacion_macrofago.pdf

  20. Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood. 2015 [Acceso 05/06/2020];125(9):2908-14. Disponible en: https://ashpublications.org/blood/article/125/19/2908/34267/How-I-treat-hemophagocytic-lymphohistiocytosis-in

  21. Stoll ML, Cron RQ. Treatment of Juvenile Idiopathic Arthritis. Rheum Dis Clin N Am. 2013 [Acceso 05/06/2020];39:751-66. DOI: http://dx.doi.org/10.1016/j.rdc.2013.05.004

  22. Conde LF, Aedoa K, Miraval P, Niño de Guzmán T. Síndrome de activación macrofágica: experiencia sobre el cuestionado papel del etopósido. Reumatología Clínica. 2017 [Acceso 05/06/2020];13(4):239-40. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=3122120




2020     |     www.medigraphic.com